ADISINSIGHT (Adis R&D Insight)

Subject Coverage
Weekly reports on new drugs in research, changes in development phases, and licensing availability

File Type
Substance, Full Text

Features

- Alerts (SDI) Weekly
- CAS Registry Number® Identifiers
- Page Images
- STN® AnaVist™
- Keep & Share Weekly
- SLART
- STN Easy®
- Learning Database
- Structures

Record Content
- Full text reports, i.e., profiles, on drugs in active research and development by the international pharmaceutical industry
- Generic names, synonyms, trade names
- CAS Registry Numbers®
- EphMRA ATC codes, WHO ATC codes
- Developing companies, development stages by indication and country
- Licensed forecast information from Lehman Brothers
- Adis's own unique therapeutic value rating

File Size
More than 42,880 records (8/18)

Coverage
1998 to the present

Updates
Weekly

Language
English

Database Producer
Springer International Publishing AG

Copyright Holder

Contact Springer Online Services support desk:
Email: onlineservice@springer.com
Phone: +49 6221 345 4303 (Europe/Asia/Africa)
        +1 800 777 4643 (North & South America)

Sources
- Direct contact with companies involved with research and development
- 1,700 biomedical and medical journals
- International meetings and conferences
- Company annual reports
- News services
- Press releases
- Licensed Lehman Brothers' PharmaPipelines data
User Aids

- Online Helps (HELP DIRECTORY lists all help messages available)
- STNGUIDE

Clusters

- ADISBASES
- BIOSCIENCE
- CASRNS
- COMPANIES
- FORMULATION
- FULLTEXT
- HEALTH
- MEDICINE
- PHARMACOLOGY
- TOXICOLOGY

STN Database Clusters information (PDF).

Pricing

Enter HELP COST at an arrow prompt (=>).
# Search and Display Field Codes

The following fields that allow left truncation (/BI, /CNS and /RNTE) are marked with an asterisk.

<table>
<thead>
<tr>
<th>Search Field Name</th>
<th>Search Code</th>
<th>Search Examples</th>
<th>Display Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic Index* (contains single words from the classification code (CC), development status (DSTA), text (TX), revision note (RNTE), company name (CO), chemical name (CN), controlled term (CT), and geographic term (GT) fields, as well as molecular formulas (MF) and CAS Registry Numbers (RN))</td>
<td>None (or /BI)</td>
<td>S IMMUNOSTIMULANTS</td>
<td>CC, CN, CO, DSTA, MF, RN, RNTE, TX</td>
</tr>
<tr>
<td>Accession Number (1)</td>
<td>/AN</td>
<td>S 1998:9493/AN</td>
<td>AN</td>
</tr>
<tr>
<td>Change Date (1)</td>
<td>/CDAT</td>
<td>S CDAT&gt;19980100</td>
<td>CDAT</td>
</tr>
<tr>
<td>Chemical Name (includes chemical names, generic names, synonyms, and trade names)</td>
<td>/CN</td>
<td>S POLOXAMER 188 NF/CN</td>
<td>CN</td>
</tr>
<tr>
<td>Chemical Name Segment*</td>
<td>/CNS</td>
<td>S (METHYL (L) THIAZOL)/CNS</td>
<td>CN</td>
</tr>
<tr>
<td>Classification Code (EphMRA ATC codes and WHO ATC codes) (code and text) (2)</td>
<td>/CC</td>
<td>S ?AMINOBUTYRYL?/CNS</td>
<td>CC</td>
</tr>
<tr>
<td>Company Name (2) (corporate name and location)</td>
<td>/CO</td>
<td>S SMITHKLINE UNITED KINGDOM/CO</td>
<td>CO</td>
</tr>
<tr>
<td>Controlled Term (indication)</td>
<td>/CT</td>
<td>S ALZHEIMER?/CT</td>
<td>DSTA</td>
</tr>
<tr>
<td>Development Status (development phase, location, and indication)</td>
<td>/DSTA</td>
<td>S (PHASE II (L) GERMANY)/DSTA</td>
<td>DSTA</td>
</tr>
<tr>
<td>Document Number</td>
<td>/DN</td>
<td>S 002345/DN</td>
<td>DN</td>
</tr>
<tr>
<td>Element Count, Specific (1)</td>
<td>/Element symbol</td>
<td>S 1/N AND 3/O</td>
<td>MF</td>
</tr>
<tr>
<td>Entry Date (1)</td>
<td>/ED</td>
<td>S L1 AND ED&gt;=19990700</td>
<td>Not displayed</td>
</tr>
<tr>
<td>Field Availability (code and text)</td>
<td>/FA</td>
<td>S EVALUATION/FA</td>
<td>FA</td>
</tr>
<tr>
<td>Geographic Term (code and text)</td>
<td>/GT</td>
<td>S GERMANY/GT</td>
<td>DSTA</td>
</tr>
<tr>
<td>Highest Development Phase (code and text)</td>
<td>/HDP</td>
<td>S PHASE III/HDP</td>
<td>HDP</td>
</tr>
<tr>
<td>Journal Title</td>
<td>/JT</td>
<td>S ADIS R&amp;D INSIGHT/JT</td>
<td>JT, SO</td>
</tr>
<tr>
<td>Molecular Formula</td>
<td>/MF</td>
<td>S C10H10N2O5/MF</td>
<td>MF</td>
</tr>
<tr>
<td>Number of Components (1)</td>
<td>/NC</td>
<td>S 6 AND NC&gt;=2</td>
<td>MF</td>
</tr>
<tr>
<td>Other Source (Adis Alerts Accession Number)</td>
<td>/OS</td>
<td>S &quot;8000073511&quot;/OS</td>
<td>OS</td>
</tr>
<tr>
<td>Periodic Group</td>
<td>/PG</td>
<td>S T3/PG</td>
<td>MF</td>
</tr>
<tr>
<td>Reference</td>
<td>/RE</td>
<td>S JOURNAL OF PHARMACOLOGY/RE</td>
<td>RE</td>
</tr>
<tr>
<td>Revision Date (1)</td>
<td>/RDAT</td>
<td>S 19980312/RDAT</td>
<td>RDAT</td>
</tr>
</tbody>
</table>
### Search and Display Field Codes (cont’d)

<table>
<thead>
<tr>
<th>Search Field Name</th>
<th>Search Code</th>
<th>Search Examples</th>
<th>Display Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revision Note*</td>
<td>/RNTE</td>
<td>S PRECLINICAL DEV?/RNTE</td>
<td>RNTE</td>
</tr>
<tr>
<td>Source</td>
<td>/SO</td>
<td>S ADIS R&amp;D INSIGHT/SO</td>
<td>SO</td>
</tr>
<tr>
<td>Trade Name</td>
<td>/TN</td>
<td>S TANADOPA/TN</td>
<td>CN</td>
</tr>
<tr>
<td>Update Date (1)</td>
<td>/UP</td>
<td>S L1 AND UP&gt;=19990600</td>
<td>Not displayed</td>
</tr>
<tr>
<td>Word Count (1)</td>
<td>/WC</td>
<td>S L1 AND WC</td>
<td>WC</td>
</tr>
</tbody>
</table>

(1) Numeric search field that may be searched using numeric operators or ranges.
(2) Implied (S) proximity is available in this field.
(3) This score is only available in selected records published in November 2010 and earlier.

### DISPLAY and PRINT Formats

Any combination of formats may be used to display or print answers. Multiple codes must be separated by spaces or commas, e.g., D L1 1-5 CN TX. The fields are displayed or printed in the order requested.

Hit-term highlighting is available for all fields except FA, STF, STR, and STS. Highlighting must be ON during SEARCH in order to use the HIT, KWIC, and OCC formats.

<table>
<thead>
<tr>
<th>Format</th>
<th>Content</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>AN</td>
<td>Accession Number</td>
<td>D AN</td>
</tr>
<tr>
<td>CC</td>
<td>Classification Code (EphMRA ATC codes and WHO ATC codes)</td>
<td>D 1-3 CC</td>
</tr>
<tr>
<td>CDAT (1)</td>
<td>Change Date</td>
<td>D CDAT</td>
</tr>
<tr>
<td>CN</td>
<td>Chemical Name (Generic Names, Synonyms, Chemical Name, and Trade Names) (includes TN)</td>
<td>D CN STR</td>
</tr>
<tr>
<td>CO</td>
<td>Company Name (corporate name and location) (Originator, Parent, Licensee, and Other)</td>
<td>D CO 1,3-5</td>
</tr>
<tr>
<td>DN</td>
<td>Document Number</td>
<td>D AN DN</td>
</tr>
<tr>
<td>DSTA</td>
<td>Development Status (development status, location, and indication)</td>
<td>D DSTA</td>
</tr>
<tr>
<td>FA (2)</td>
<td>Field Availability</td>
<td>D FA</td>
</tr>
<tr>
<td>HDP</td>
<td>Highest Development Phase</td>
<td>D HDP</td>
</tr>
<tr>
<td>JT (2)</td>
<td>Journal Title</td>
<td>D JT 2</td>
</tr>
<tr>
<td>MF</td>
<td>Molecular Formula</td>
<td>D CN MF</td>
</tr>
<tr>
<td>OS</td>
<td>Other Source (Adis Alerts Accession Number)</td>
<td>D OS</td>
</tr>
<tr>
<td>RDAT (RNTE)</td>
<td>Revision Date and Revision Note</td>
<td>D RDAT</td>
</tr>
<tr>
<td>RE</td>
<td>Reference</td>
<td>D RE L1 4</td>
</tr>
<tr>
<td>RN</td>
<td>CAS Registry Number and Related CAS Registry Number</td>
<td>D RN 3,4</td>
</tr>
<tr>
<td>SO</td>
<td>Source</td>
<td>D SO</td>
</tr>
<tr>
<td>STF</td>
<td>Flat Structure (no stereo indicated)</td>
<td>D L9 1 3</td>
</tr>
<tr>
<td>STR (3)</td>
<td>Structure Diagram (includes stereo bonds and R/S/E/Z labels when available)</td>
<td>D L4 STR</td>
</tr>
<tr>
<td>STS (2,3)</td>
<td>Stereo Structure (includes stereo bonds when available)</td>
<td>D STS</td>
</tr>
<tr>
<td>TN (2)</td>
<td>Trade Name</td>
<td>D TN</td>
</tr>
<tr>
<td>TX</td>
<td>Text (Introduction, Evaluation, Commercial Summary (table with Company, Major Markets, Launch Date, Commercial Value, and Patent Expiry), Pharmacology Overview (Mechanism of action, Route of Elimination), Clinical Overview, Adverse Events, Pharmacology (Pharmacokinetics, Clinical Studies), and Therapeutic Trials) (includes EVAL)</td>
<td>D TX</td>
</tr>
<tr>
<td>WC</td>
<td>Word Count</td>
<td>D WC</td>
</tr>
<tr>
<td>ALL (3)</td>
<td>AN, SO, DN, CDAT, CN, MF, RN, STR, related RN, CC, HDP, DSTA, CO, OS, WC, TX, RDAT, RNTE, RE</td>
<td>D ALL</td>
</tr>
<tr>
<td>DALL (3)</td>
<td>ALL, delimited for post-processing</td>
<td>D DALL</td>
</tr>
<tr>
<td>IALL (3)</td>
<td>ALL, indented with text labels</td>
<td>D IALL</td>
</tr>
<tr>
<td>IDE (3)</td>
<td>AN, SO, DN, CDAT, CN, MF, RN, STR, related RN, CC, HDP, CO, OS, WC</td>
<td>D IDE</td>
</tr>
<tr>
<td>IIDE (3)</td>
<td>IDE, indented with text labels (IIDE is the default)</td>
<td>D L2 3 IIDE</td>
</tr>
<tr>
<td>ISTD (3)</td>
<td>STD, indented with text labels</td>
<td>D ISTD</td>
</tr>
</tbody>
</table>

---

August 2018
### DISPLAY and PRINT Formats (cont'd)

<table>
<thead>
<tr>
<th>Format</th>
<th>Content</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCAN (1,4) STD (3)</td>
<td>CN (Generic Name) (random display, no answer number) AN, SO, DN, CDAT, CN, MF, RN, STR, related RN, CC, HDP, DSTA, CO, OS, WC, TX</td>
<td>D SCAN D STD</td>
</tr>
<tr>
<td>TRIAL (1) (SAM, TRI)</td>
<td>CN (Generic Name), CDAT</td>
<td>D TRIAL TOTAL</td>
</tr>
<tr>
<td>HIT</td>
<td>Fields containing hit terms</td>
<td>D HIT</td>
</tr>
<tr>
<td>KWIC</td>
<td>Hit terms with 20 words on either side (KeyWord-In-Context)</td>
<td>D KWIC NOH</td>
</tr>
<tr>
<td>OCC (1)</td>
<td>Number of occurrences of hit terms and fields in which they occur</td>
<td>D OCC</td>
</tr>
</tbody>
</table>

(1) No online display fee for this format.  
(2) Custom display format only.  
(3) Stereo structure diagrams are available only on graphics terminals and offline prints.  
(4) SCAN must be entered on the command line, i.e., DISPLAY SCAN, D SCAN.

### SELECT, ANALYZE, and SORT Fields

The **SELECT** command is used to create E-numbers containing terms taken from the specified field in an answer set.

The **ANALYZE** command is used to create an L-number containing terms taken from the specified field in an answer set.

The **SORT** command is used to rearrange the search results in either alphabetic or numeric order of the specified field(s).

<table>
<thead>
<tr>
<th>Field Name</th>
<th>Field Code</th>
<th>ANALYZE/SELECT (1)</th>
<th>SORT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accession Number</td>
<td>AN</td>
<td>Y</td>
<td>N</td>
</tr>
<tr>
<td>CAS Registry Number</td>
<td>RN</td>
<td>Y (2)</td>
<td>N</td>
</tr>
<tr>
<td>CAS Registry Number and Chemical Name</td>
<td>CHEM</td>
<td>Y (3)</td>
<td>N</td>
</tr>
<tr>
<td>Change Date</td>
<td>CDAT</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>Chemical Name</td>
<td>CN</td>
<td>Y (4)</td>
<td>Y</td>
</tr>
<tr>
<td>Classification Code (EphMRA and WHO ATC codes)</td>
<td>NAME</td>
<td>Y (5)</td>
<td>N</td>
</tr>
<tr>
<td>Company Name (Corporation Name)</td>
<td>CC</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>Controlled Term (Indication)</td>
<td>CO</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>Development Status</td>
<td>CT</td>
<td>Y (6)</td>
<td>N</td>
</tr>
<tr>
<td>Document Number</td>
<td>DSTA</td>
<td>Y</td>
<td>N</td>
</tr>
<tr>
<td>Geographic Term</td>
<td>JT</td>
<td>Y (6)</td>
<td>N</td>
</tr>
<tr>
<td>Highest Development Phase</td>
<td>HDP</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>Journal Title</td>
<td>MF</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>Molecular Formula</td>
<td>OCC</td>
<td>N</td>
<td>Y</td>
</tr>
<tr>
<td>Occurrence Count of Hit Terms</td>
<td>OS</td>
<td>Y (7)</td>
<td>Y</td>
</tr>
<tr>
<td>Other Source (Adis Alerts Accession Number)</td>
<td>RE</td>
<td>Y</td>
<td>N</td>
</tr>
<tr>
<td>Reference</td>
<td>RDAT</td>
<td>Y (6)</td>
<td>N</td>
</tr>
<tr>
<td>Revision Date</td>
<td>RNTE</td>
<td>Y (6)</td>
<td>N</td>
</tr>
<tr>
<td>Revision Note</td>
<td>SO</td>
<td>Y</td>
<td>N</td>
</tr>
<tr>
<td>Source</td>
<td>TX</td>
<td>Y (8)</td>
<td>N</td>
</tr>
<tr>
<td>Text</td>
<td>TN</td>
<td>Y</td>
<td>N</td>
</tr>
<tr>
<td>Trade Name</td>
<td>WC</td>
<td>N</td>
<td>Y</td>
</tr>
<tr>
<td>Word Count</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(1) HIT may be used to restrict terms extracted to terms that match the search expression used to create the answer set, e.g., SEL HIT CN.  
(2) Selects or analyzes the CAS Registry for the substance and the related CAS Registry Numbers with /BI appended to the terms created by SELECT.
(3) Selects or analyzes the CAS Registry for the substance, the related CAS Registry Numbers, Generic Names, Synonyms, Chemical Name, and Trade Names) with /BI appended to the terms created by SELECT.

(4) Selects or analyzes the Generic Names, Synonyms, Chemical Name, and Trade Names).

(5) Selects or analyzes the Generic Names, Synonyms, Chemical Name, and Trade Names with /BI appended to the terms created by SELECT.

(6) SELECT HIT and ANALYZE HIT are not valid with this field.

(7) Appends /DN to the terms created by SELECT.

(8) Appends /BI to the terms created by SELECT.

### Full-Text Browsing

<table>
<thead>
<tr>
<th>User Request</th>
<th>Example</th>
<th>System Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>DISPLAY BROWSE</td>
<td>=&gt; DISPLAY BROWSE</td>
<td>NOVICE version</td>
</tr>
<tr>
<td></td>
<td>ENTER (L1) OR L#:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ENTER (DIS), ANSWER NUMBERS, OR END:</td>
<td></td>
</tr>
<tr>
<td>D BRO</td>
<td>=&gt; D BRO L1</td>
<td>EXPERT version</td>
</tr>
<tr>
<td>Answer number(s)</td>
<td>:1-3</td>
<td></td>
</tr>
<tr>
<td>Answer number(s) and format</td>
<td>:4 HIT</td>
<td></td>
</tr>
<tr>
<td>Format only</td>
<td>:TI TX</td>
<td></td>
</tr>
<tr>
<td>Change default format</td>
<td>:KWIC</td>
<td></td>
</tr>
<tr>
<td>Forward n fields</td>
<td>:F3</td>
<td></td>
</tr>
<tr>
<td>Backward n fields</td>
<td>:B1</td>
<td></td>
</tr>
<tr>
<td>Search forward for character</td>
<td>:S BONE MARROW</td>
<td></td>
</tr>
<tr>
<td>Search backward for character</td>
<td>:S -NAUSEA</td>
<td></td>
</tr>
<tr>
<td>string</td>
<td>:END</td>
<td></td>
</tr>
<tr>
<td>End DISPLAY BROWSE</td>
<td>=&gt;</td>
<td></td>
</tr>
</tbody>
</table>
Sample Records

DISPLAY ALL
AN 1998:1 ADISINSIGHT
SO Adis R&D Insight
DN 000001
CDAT Sep 14, 2016
CN Benidipine
CN Benidipine hydrochloride; KW 3049; KW3049; Nacadipine; Nakadipine
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-
   , methyl 1-(phenylmethyl)-3-piperidinyl ester, monohydrochloride,
   (R*,R*)-(-)-
CN Caritec(R); Coniel(R)
MF C28 H31 N3 O6 . Cl H
RN 91599-74-5
STR

Relative stereochemistry.

RN 105979-17-7 (Benidipine)
CC EPHMRA ATC CODE: C8A Calcium Antagonists, Plain
CC WHO ATC CODE: C08C-A Dihydropyridine derivatives
HDP Launched
DSTA Launched, China, Angina pectoris
   Launched, India, Angina pectoris
   Launched, Japan, Angina pectoris
   Launched, Philippines, Angina pectoris
   Launched, Turkey, Angina pectoris
   Launched, China, Essential hypertension
   Launched, India, Essential hypertension
   Launched, Japan, Essential hypertension
   Launched, Philippines, Essential hypertension
   Launched, Turkey, Essential hypertension
Discontinued III, Italy, Angina pectoris
Discontinued III, Italy, Essential hypertension
Discontinued II, Germany, Angina pectoris
Discontinued II, United Kingdom, Angina pectoris
Discontinued II, United States, Angina pectoris
Discontinued II, Germany, Essential hypertension
Discontinued II, United Kingdom, Essential hypertension
Discontinued II, United States, Essential hypertension

ORIGINATOR: Kyowa Hakko (Japan)
PARENT: Kyowa Hakko
LICENSEE: Bristol-Myers Squibb; Deva Holding; Sun Pharmaceutical Industries

TX TEXT
Introduction:
Company Agreements

In October 2013, Bristol-Myers Squibb licensed the exclusive Chinese marketing rights for benidipine from Kyowa Hakko Kirin. Financial details of the agreement were not disclosed/1/.

Benidipine appears to have been licensed to Deva (an EastPharma subsidiary) for commercialisation in Turkey, and to Sun Pharmaceutical Industries for commercialisation in India.

Crinos (later Sirton Pharmaceuticals) had licensed benidipine for development in Italy. However, this agreement no longer appears to be active.

In March 2015, Sun Pharmaceutical Industries acquired Ranbaxy/2/.

Introduction

Benidipine is an orally bioavailable dihydropyridine antagonist of L-type, N-type and T-type calcium channels. The drug was developed by Kyowa Hakko (now Kyowa Hakko Kirin) for the treatment of essential hypertension and angina pectoris, and gained approval in Japan in 1991. It has subsequently been launched in Japan, China, Philippines and Turkey (as Coniel sup(R)), and in India (as Caritec sup(R)) for these indications.

In October 2008, Kyowa Hakko merged with Kirin Pharma to form Kyowa Hakko Kirin/3/.

Generic versions of Coniel sup(R) were launched in Japan in July 2006, following expiry of patent protection in the region.

Key Development Milestones

Benidipine was approved in China in September 2008 for the treatment of angina pectoris, following the filing of an application for regulatory approval in 2007/4/. The drug had been launched in China for the treatment of hypertension in December 2004, after gaining regulatory approval in March 2004. Kyowa Hakko had launched benidipine in the Philippines for both indications by April 2002.

In July 2006, Deva was granted marketing authorisation for benidipine in angina pectoris and essential hypertension, and subsequently launched the product in that country during 2007. Ranbaxy launched the drug in India, in October 2000.

Kyowa Hakko announced in its 2003 annual report that a special investigation evaluating the efficacy and safety of long-term (1 year) administration of benidipine in 10 000 older patients with hypertension had been initiated. A second large-scale clinical trial in collaboration with Yamaguchi University had also been initiated to investigate benidipine in combination with one of three types of antihypertensives (beta-blockers, angiotensin II receptor blockers and antihypertensive diuretics) over a three-year period (COPE; NCT00135551). The effectiveness and safety of the three combination regimens was to be compared and evaluated. This trial enrolled 3501 patients with hypertension in Japan, and was completed in November 2010.

Benidipine was undergoing phase III clinical trials in Italy and phase II trials in Germany, the United Kingdom and the USA for angina pectoris and essential hypertension. However, development appears to have been discontinued in these countries.

TX PHARMACOLOGY OVERVIEW:
Pharmacodynamics:
Coronary and cerebral vasodilatory effects in vivo; marked BP-lowering effects; diuresis; natriuresis
Mechanism of action:
L-type calcium channel antagonists
L-type calcium channel modulators
Calcium channel antagonists
Calcium channel modulators
Ion channel antagonists
Ion channel modulators
Membrane glycoprotein inhibitors
Membrane transport protein inhibitors
Membrane glycoprotein modulators
Membrane transport protein modulators
Glycoprotein inhibitors
Membrane protein inhibitors
Carrier protein inhibitors
Glycoprotein modulators
Membrane protein modulators
Carrier protein modulators
Protein inhibitors
Glycoconjugate inhibitors
Glycoconjugate modulators
Protein modulators
Carbohydrate metabolism inhibitors

Carbohydrate metabolism modulators
N-type calcium channel antagonists
N-type calcium channel modulators
Calcium channel antagonists
Calcium channel modulators
Ion channel antagonists
Ion channel modulators
Membrane glycoprotein inhibitors
Membrane transport protein inhibitors
Membrane glycoprotein modulators
Membrane transport protein modulators
Glycoprotein inhibitors
Membrane protein inhibitors
Carrier protein inhibitors
Glycoprotein modulators
Membrane protein modulators
Carrier protein modulators
Protein inhibitors
Glycoconjugate inhibitors
Glycoconjugate modulators
Protein modulators
Carbohydrate metabolism inhibitors

Carbohydrate metabolism modulators
T-type calcium channel antagonists
T-type calcium channel modulators
Calcium channel antagonists
Calcium channel modulators
Ion channel antagonists
Ion channel modulators
Membrane glycoprotein inhibitors
Membrane transport protein inhibitors
Membrane glycoprotein modulators
Membrane transport protein modulators
Glycoprotein inhibitors
Membrane protein inhibitors
Carrier protein inhibitors
Glycoprotein modulators
Membrane protein modulators
Carrier protein modulators
Protein inhibitors
Glycoconjugate inhibitors
Glycoconjugate modulators
Protein modulators
Carbohydrate metabolism inhibitors

Carbohydrate metabolism modulators
Activity versus parent drug: unspecified parent
CLINICAL OVERVIEW:
Route(s) of Administration: PO
Adverse events:
rare: Diarrhoea, Oedema.
Drug Interactions:
Unknown.

Adverse Events:
In 55 patients with essential hypertension receiving benidipine 2-8 mg/day for <= 1 year, adverse events included lightheadedness (n = 1), diarrhoea (1) and peripheral oedema (1)/5/.

PHARMACOLOGY:
Pharmacodynamics (Hypertension):
Preclinical studies: the long term effects of ceronaprile 40 mg/kg/day, AE 0047 20 mg/kg/day and benidipine 10 or 20 mg/kg/day were examined in stroke-prone spontaneously hypertensive rats. In treated rats, the incidence of cerebrovascular lesions was significantly depressed and their life-spans were extended compared to the untreated control rats. AE 0047 sustained BP under 210mm Hg without developing fibrinoid deposition on arterial walls. After benidipine, thickened arterial walls were observed and BP remained over 250mm Hg. In contrast to benidipine, ceronapril reduced the occurrence of smooth muscle proliferation and BP levels were similar to those of benidipine/6/.

Clinical studies: a randomised, single-blind, crossover study in 15 salt-sensitive patients with essential hypertension assessed the efficacy of benidipine and controlled release nifedipine on sodium-induced changes in systemic and regional haemodynamics. Oral benidipine 4-8 mg/day once daily for 73 days significantly reduced MAP and increased CI, superior mesenteric blood flow and renal blood flow during low and high sodium intake. Nifedipine 10-30 mg/day also significantly reduced MAP during low sodium intake, but had no effects on HR, CI or regional blood flow. The high sodium diet increased MAP, CI and terminal aortic flow (all p < 0.05), and reduced mesenteric and renal blood flows (p < 0.05) during nifedipine administration/7/.

In 15 patients with essential hypertension, benidipine 4 mg/day and trandolapril 1 mg/day for 12 weeks similarly decreased BP, and increased concentrations of nitrite/nitrate (NOx) and cGMP. Neither agent affected HR, lipid profiles and renal functions/8/.

In 10 elderly patients with essential hypertension undergoing mental arithmetic test, administration of oral benidipine 4mg od for 12 weeks significantly decreased 24-h BP, and had no marked effect on HR. However, the decrease in night-time DBP was not significant, and the decrease in night-time SBP was minimal. In benidipine recipients, the increase in SBP induced by mental arithmetic test was significantly decreased compared with baseline/9/.

Pharmacodynamics (Ischaemic Heart Disease):
Benidipine suppresses ischaemic ECG changes and attenuates ST and T wave elevation in animal models. Mild and long lasting dose-dependent increases in coronary sinus outflow and decreases in BP are seen at doses > 1 microg/kg IV. Benidipine protects the ischaemic canine myocardium and maintains global cardiohaemodynamics. Other animal studies have shown that benidipine exhibits preferential coronary and cerebral vasodilating activity, and has a longer duration of action than nifedipine or nicardipine.

THERAPEUTIC TRIALS:
Hypertension:
In patients with essential hypertension (n = 21), oral once daily benidipine 4 mg/day for 2 weeks produced a long lasting reduction in BP
In an open, multicentre study in 78 patients with essential hypertension, monotherapy with oral benidipine 2-8 mg/day od for <= 1 year significantly decreased BP from baseline. Similar effect was achieved when benidipine was used in combination with other antihypertensive agents (n = 19) (details not provided). 42% of patients in the benidipine monotherapy group and 44% of patients in the combination therapy group had their BP normalised at 1 year (BP < 150/90mm Hg).

In a randomised study in 86 patients with essential hypertension, beta-blockers arotinolol, bisoprolol, ACE inhibitors captopril, imidapril and calcium antagonists nisoldipine and benidipine for 12 weeks significantly and similarly decreased 24h ambulatory BP. 24h HR decreased significantly with the beta-blockers arotinolol and bisoprolol. There were no differences in circadian and ultradian variations among the major first, second and third peaks of SBP, DBP and HR in patients receiving beta-blockers or ACE inhibitors. Calcium antagonists shortened the periodicity of ultradian variations in second and third peaks of SBP.

---

**RDAT** | **RNTE**
---|---
30 Oct 2000 | Launched for Angina pectoris in India (PO)
30 Oct 2000 | Launched for Essential hypertension in India (PO)
26 Jan 2000 | Two studies have been added to the Hypertension therapeutic trials section (720623, 746001)
05 Jul 1999 | Registered for Angina pectoris in India (PO)
05 Jul 1999 | Registered for Essential hypertension in India (PO)
30 Apr 1999 | A study has been added to the Hypertension pharmacodynamics section (746001)
29 Sep 1998 | A study has been added to the Hypertension pharmacodynamics section (691650)
11 Nov 1994 | A preclinical study has been added to the hypertension pharmacodynamics section (307950)
14 Sep 1994 | New profile

---

